Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

RXL vs. PRHSX: which is better?

Bottom line

RXL vs PRHSX: the short answer

RXL (ProShares Ultra Health Care) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) share a meaningful slice of their top holdings — about 69% by weight.

But PRHSX is far broader, holding 279 positions to 70 for RXL, so beyond the top names it adds exposure RXL doesn't have.

PRHSX is cheaper at 0.83% vs 0.95% — a difference of $12 a year per $10,000 invested.

Over five years, RXL returned +7.2% a year vs +4.2% for PRHSX.

Updated Nov 19, 2026

RXL vs PRHSX side by side

RXLPRHSX
TypeETFMutual fund
Fund familyProSharesT. Rowe Price
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.95%0.83%
Annual cost per $10k$95$83
10-yr cost on $10k (prospectus)$1,305$1,025
Max front loadNone—
12b-1 fee——
1-yr return+19.7%+17.7%
5-yr return (annualized)+7.2%+4.2%
10-yr return (annualized)+12.6%+9.1%
Best quarter+29.7%+23.5%
Worst quarter−28.9%−15.8%
Net assets (fund)$72.1M$11.9B
Number of holdings70279
Portfolio turnover4%62%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearRXLPRHSXDifference
2025+19.7%+17.7%+2.0%
2024−2.7%+1.8%−4.5%
2023−3.2%+3.1%−6.3%
2022−15.1%−12.2%−2.9%
2021+47.8%+13.3%+34.6%
2020+19.2%+30.1%−10.9%
2019+38.9%+29.1%+9.8%
2018+5.4%+1.2%+4.2%
2017+46.0%+28.0%+18.1%
2016−8.9%−10.4%+1.4%

Source: Fund prospectus bar charts

Holdings overlap

16 of RXL's top 25 holdings also appear in PRHSX's top 25.

Shared top holdings
HoldingRXLPRHSX
Eli Lilly & Co.12.67%14.28%
Johnson & Johnson7.86%6.63%
AbbVie, Inc.5.57%5.10%
UnitedHealth Group, Inc.4.98%5.99%
Merck & Co., Inc.4.26%4.01%
Thermo Fisher Scientific, Inc.2.68%2.52%
Amgen, Inc.2.62%1.82%
Gilead Sciences, Inc.2.41%2.82%
Intuitive Surgical, Inc.2.18%1.87%
Abbott Laboratories2.15%1.89%
Bristol-Myers Squibb Co.1.68%2.11%
CVS Health Corp.1.67%0.94%
Danaher Corp.1.66%1.43%
Vertex Pharmaceuticals, Inc.1.64%2.28%
Stryker Corp.1.52%1.78%

Source: SEC Form N-PORT

RXL top 10

  1. Eli Lilly & Co. — 12.67%
  2. ProShares GENIUS Money Market ETF — 11.81%
  3. Johnson & Johnson — 7.86%
  4. AbbVie, Inc. — 5.57%
  5. UnitedHealth Group, Inc. — 4.98%
  6. Merck & Co., Inc. — 4.26%
  7. Repurchase Agreement — 2.91%
  8. Thermo Fisher Scientific, Inc. — 2.68%
  9. Amgen, Inc. — 2.62%
  10. Gilead Sciences, Inc. — 2.41%

PRHSX top 10

  1. Eli Lilly & Co — 14.28%
  2. Johnson & Johnson — 6.63%
  3. Unitedhealth Group Inc — 5.99%
  4. Abbvie Inc — 5.10%
  5. Merck & Co. Inc. — 4.01%
  6. Gilead Sciences Inc — 2.82%
  7. Thermo Fisher Scientific Inc — 2.52%
  8. Vertex Pharmaceuticals Inc — 2.28%
  9. Bristol-myers Squibb Co — 2.11%
  10. Abbott Laboratories — 1.89%

FAQ

What is the difference between RXL and PRHSX?
RXL (ProShares Ultra Health Care) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) share a meaningful slice of their top holdings — about 69% by weight. But PRHSX is far broader, holding 279 positions to 70 for RXL, so beyond the top names it adds exposure RXL doesn't have.
Which is cheaper, RXL or PRHSX?
PRHSX has the lower expense ratio (0.83%).
Should I own both RXL and PRHSX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.